Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

APM - Aptorum Group Ltd - Ordinary Shares - Class A


Previous close
2.88
0   0%

Share volume: 5,664
Last Updated: Thu 29 Aug 2024 06:00:00 AM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$2.88
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-3.55%
1 Month
-8.28%
3 Months
-40.20%
6 Months
79.58%
1 Year
28.88%
2 Year
-79.38%
Key data
Stock price
$2.88
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$1.35 - $17.49
52 WEEK CHANGE
$0.33
MARKET CAP 
8.784 M
YIELD 
N/A
SHARES OUTSTANDING 
2.938 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$10,311
AVERAGE 30 VOLUME 
$11,884
Company detail
CEO:
Region: US
Website: http://www.aptorumgroup.com/
Employees: 24
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

aptorum group limited, a pharmaceutical company, engages in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly infectious diseases and cancers. its pipeline through the establishment of drug discovery platforms enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases. the company is also pursuing therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. it also has projects focused on surgical robotics and natural supplement for women undergoing menopause and experiencing related symptoms. aptorum group limited was incorporated in 2010 and is headquartered in london, the united kingdom.

Recent news